Two ways to establish potential At-211 radiopharmaceuticals

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1809-1813

  Wunderlich, G ^a   Franke, W G ^a   Doberenz, I ^a   Fischer, S ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

At 211; Cyclotron radionuclides; Labelling; Radionuclide therapy; Radiopharmaceutical

Indexed keywords

AROMATIC COMPOUND; ASTATINE 211; HALOGEN; IODINE DERIVATIVE; RADIOISOTOPE;

ARTICLE; CANCER RECURRENCE; CYCLOTRON; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; METABOLISM; PRIORITY JOURNAL; RADIATION PHYSICS; TONGUE CARCINOMA;

ANIMALS; ASTATINE; CYCLOTRONS; DRUG DESIGN; HUMANS; MICROSPHERES; NEOPLASMS; RADIOPHARMACEUTICALS; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 0030913395     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Beyer GJ, Dreyer R, Odrich H, Rösch F: Production of At-211 in the Rossendorf-Cyclotron U120. Radiochem Radioanal Let 77: 63-69, 1981.
2. Hamilton JG, Durbin PW, Parrott HW: Accumulation of At-211 by thyroid gland in man. Exp Biol Med 86: 366-369, 1954.
3. Bloomer WD, McLaughlin WH, Lambrecht RM: At-211 tellurium radiocolloid cures experimental malignant ascites. Science 212: 340-341, 1981.
4. Doberenz I, Wunderlich G, Doberenz W, Franke WG: Endoarterycal therapy of lingual carcinoma using At-211 labelled human serum albumin microspheres. NuC Compact 21: 124-127, 1990.
5. Cobb LM, Harrison A, Dudley NE: Relative concentration of At-211 and 1-125 by human fetal thyroid and carcinoma of the thyroid in nude mice. Radiother Onc 13: 203-209, 1989.
6. Hadley SW, Wilbur DS, Gray MA, Atcher RW: At-211 labelling of an antimelanoma antibody and its Fab fragment using N-succinimidyl pastatobezoate. Bioconjugate Chem 2: 171-179, 1991.
7. 2. Nucl Med Biol 20: 917-927, 1993.
8. 2fragment labelled with N-succinimidyl-2,4-dimethoxy-3-halobenzoates. Nucl Med Biol 21: 105-110, 1994.
9. Neirinkx RD, Myburgh JA, Smit JA: Labelling of lymphozytes with At-211 and its application in transplantation. Procc Symp Radiopharm Lab Comp Vienna Vol 2: 171-180, 1973.
10. Meyer GJ, Rossler K, Stocklin GA: The reactivity and selectivity of inorganic forms of the radioelement astatine in the labelling of simple aromatic systems and biomolecules. Report AED-Conf-75- 404 029: 9pp, 1975.
11. Rossler K, Meyer GJ, Stocklin G: Labelling and animal distribution studies of 5-astatouracil and 5-astatodeoxyuridine. J Lab Comp Radiopharm 13: 271, 1977.
12. Friedman AM, Zalutsky MR, Wung W: Preparation of a biologically stable and immunogenically competent astatinated protein. Int J Nucl Med Biol 4: 219-224, 1977.
13. Zalutsky MR, Narula AS: A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Rad Isot 38: 1051-1055, 1987.
14. Mertens J, Vanryckeghem W, Gysemans M, Carlsen L: New fast preparations of 1-123 labelled radiopharmaceuticals. Eur J Nucl Med 13: 380-381, 1987
15. Brown I, Carpenter RN, Link E, Mitchell JS: Potential diagnostic and therapeutic agents for malignant melanoma. J Radioanal Nucl Chem. Lett 107: 319-332, 1985.
16. Vaidyanathan G, Zalutsky MR: m-Astatobenzylguanidine: Synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. Bioconjugate Chem 3: 499-503, 1992.
17. Brown I, Carpenter RN, Mitchell JS: High LET endoradiotherapy: studies with an astatinated anti tumour drug. Int J Radiat Biol 45: 547, 1984.
18. Wunderlich G, Franke WG, Fischer S, Dreyer R: Animal studies on the in vivo stability of At-211 labelled albumin particles Nucl Med Comm 7: 211-214, 1986.
19. Wunderlich G, Fischer S, Dreyer R, Doberenz W: Processing and in vivo behaviour of At-211 labelled colloids and albumin particles of different size. Radiochim Acta 47: 153-155, 1989.
20. Vergote I, Larsen RH, De Vos L, Winderen M, Ellingsen T: Distribution of intraperitoneally injected microspheres labelled with At-211 compared with P-32 and Y90 Colloids in mice. Gyn One 47: 358-365, 1992.
21. Wunderlich G, Franke WG, Hliscs R, Doberenz W: Incorporation dosimetry of At-211 HSA-microspheres in experimental tumour. Med Nucl 1: 25-27, 1989.
22. Shaffer R: Alpha irradiation. Effect of astatine on the anterior segment and on epithelial zyst. Tran Am Ophth Soc 50: 607-627, 1952.
23. Hamilton JG, Durbin PW, Parrott MW: Accumulation of astatine-211 by thyroid gland in man. Proc Soc Exptl Biol Med 86: 366-369, 1954.
24. Vaughan ATM, Bateman WJ, Fischer DR: The in vivo fate of astatine-211 labelled monoclonal antibody with known specifity in a murine system. Int. J Radiat One Biol Phys 8: 1943-1946, 1982.
25. Harrison A, Royle L: Preparation of a At-211 IgG conjugate which is stable in in vivo. Int J Appl Radiat Isot 35: 1005-1008, 1984.
26. Astatine. Its organo-nuclear chemistry and biomedical applications. In: Adv Inorg Chem (Emeleus HJ, Sharpe AG, eds.). New York, Academic Press, 1987, pp.43-88
27. Link E, Brown I, Carpenter RN, Mitchel JS: Uptake and therapeutic effectivness of 1-125 and At-211 methylene blue for pigmented melanoma in an animal model system. Cancer Res 49: 4332-4337, 1989.
28. Doberenz I, Doberenz W, Wunderlich G, Franke WG: Animal experiments on pigs using HSA-microspheres labelled with At-211 regarding the introduction of endoarterial therapy. Nuc Compact 19: 105-108, 1988.